TrialCurveJCOG1306: reconstructed Kaplan–Meier curves
Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Br J Cancer. 2022 Jul 23;127(8):1487–96. doi: 10.1038/s41416-022-01912-5 |
|---|---|
| DOI | 10.1038/s41416-022-01912-5 |
| Registry | — |
| Phase | — |
| Conditions | — |
| Interventions | — |
| Sponsor | — |
| Enrolment | — |
| Source licence | Figure published under CC BY 4.0 |
Overall survival
From figure panel a · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: AI not reached; GD not reached. Survival at 1 years: AI 100%; GD 99%. Hazard ratio AI vs GD 0.39 (95% CI 0.12–1.25).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| AI | 70 | 4 | not reached |
| GD | 73 | 10 | not reached |
- AI vs GD: reconstructed HR 0.39 (95% CI 0.12–1.25)
Landmark survival (reconstructed)
| Time | AI | GD |
|---|---|---|
| 1 yr | 100.0% | 98.6% |
| 2 yr | 94.1% | 91.5% |
| 3 yr | 91.4% | 79.6% |
Checks against the published figure
- hazard ratio (direction inferred): printed 2.55, reconstructed 2.56 pass
Progression-free survival
From figure panel b · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: AI not reached; GD 4.3 years. Survival at 1 years: AI 91%; GD 79%. Hazard ratio AI vs GD 0.43 (95% CI 0.23–0.82).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| AI | 70 | 14 | not reached |
| GD | 73 | 29 | 4.3 |
- AI vs GD: reconstructed HR 0.43 (95% CI 0.23–0.82)
Landmark survival (reconstructed)
| Time | AI | GD |
|---|---|---|
| 1 yr | 91.0% | 78.6% |
| 2 yr | 81.7% | 64.2% |
| 3 yr | 79.0% | 59.3% |
Checks against the published figure
- hazard ratio (direction inferred): printed 2.32, reconstructed 2.32 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/jcog1306-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/jcog1306-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Br J Cancer. 2022 Jul 23;127(8):1487–96. doi: 10.1038/s41416-022-01912-5 doi:10.1038/s41416-022-01912-5. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/jcog1306
Report a problem with these data
Related trials
- KHBO1401-MITSUBA: Overall survival; Progression-free survival
- JCOG0905: Disease-free survival; Disease-free survival (good responders); Overall survival; Overall
- GENERATE: Overall survival (planned interim analysis); Overall survival (updated analysis); Progress
- ADIUVO: Overall survival; Recurrence-free survival
- CONFIRM: Overall survival; Progression-free survival
- Convalescent plasma for severe COVID-19 in cancer patients: Overall survival (secondary endpoint)
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials